ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/KAT6-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/KAT6-inhibitor
3
trial(s) found.
NCT07062965
Advanced
Phase 3
Recruiting
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy (
C4551002
)
KAT6A/B inhibitor
KAT6 inhibitor
selective estrogen receptor degrader
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06784193
Advanced
Phase 1
Recruiting
A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors (
OP-3136-101
)
KAT6A/B inhibitor
KAT6 inhibitor
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04606446
Advanced
Phase 2
Recruiting
A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (
KAT6
)
KAT6A/B inhibitor
KAT6 inhibitor
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Recruitment Country and State
SA (3)
VIC (2)
NZ (1)
QLD (1)
WA (1)
Phase
Phase 1 (1)
Phase 2 (1)
Phase 3 (1)
Trial Type
Advanced (3)
Cancer Therapy Class
ER
100%
KAT6A
100%
oestrogen axis
100%
mTOR
33%
mTORC1
33%
CDK4
33%
CDK4 selective
33%
CDK6
33%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Castrate-resistant prostate cancer
Lung cancer
Male genital cancers
Non-small cell lung cancer
Prostate adenocarcinoma
Prostate cancer
Respiratory tract cancer
Thoracic cancer
Urogenital cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy